Filing Analysis
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the second quarter of 2026. The filing serves as a placeholder for the press release containing the company's operational and financial performance data.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Second Quarter of 2026
- The filing includes non-GAAP financial measures with reconciliations provided in Exhibit 99.1
- Signed by Javier Rampolla, Chief Financial Officer
Sensus Healthcare entered into a new $15 million revolving credit facility with City National Bank of Florida on June 2, 2026, to replace a previously terminated facility with Fifth Third Bank.
🚩 Red Flags
- The loan is secured by a blanket lien on all company assets ('all of the Company’s assets').
- Restrictive covenants prevent the company from removing the CEO, President, or CFO without bank consent.
- The company's previous credit facility with Fifth Third Bank was terminated, indicating a need for urgent refinancing.
📋 Key Facts
- Maximum borrowings under the new revolving credit facility are $15,000,000.
- Interest rate is set at Secured Overnight Financing Rate (SOFR) plus 3% per annum.
- Maturity date is June 5, 2027.
- The loan is secured by $2,230,000 in cash collateral and a security interest in all Company assets.
- Financial covenant requires a minimum debt service coverage ratio of 1.50.
Sensus Healthcare reported the results of its Annual Meeting of Stockholders held on May 29, 2026. The meeting resulted in the re-election of two Class II directors, the approval of executive compensation on an advisory basis, and the ratification of the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on May 29, 2026.
- Eric Sachetta and Michael J. Sardano were elected as Class II directors for three-year terms expiring in 2029.
- Executive compensation for 2025 was approved on a non-binding advisory basis (4,740,572 votes For vs 856,128 Against).
- Carr, Riggs & Ingram, LLC was ratified as the independent registered public accountant for the fiscal year ending December 31, 2026.
Sensus Healthcare, Inc. reported its financial results for the first quarter of 2026 on May 7, 2026. The filing serves as a formal disclosure of the company's quarterly performance via a press release.
📋 Key Facts
- The report was filed on May 7, 2026, covering the first quarter of the 2026 fiscal year.
- The filing includes a press release (Exhibit 99.1) which contains non-GAAP financial measures and reconciliations.
- The report was signed by Javier Rampolla, the Chief Financial Officer.
- The information is furnished under Item 2.02 (Results of Operation and Financial Condition).
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2025.
📋 Key Facts
- Financial results announced for the quarter and year ended December 31, 2025.
- Filing date: February 12, 2026.
- Includes non-GAAP financial measures with reconciliations provided in Exhibit 99.1.
Sensus Healthcare, Inc. has dismissed its independent auditor, Berkowitz Pollack Brant Advisors + CPAs, LLP (BPB), and appointed Carr, Riggs & Ingram, LLC (CRI) following CRI's acquisition of BPB's capital markets practice assets.
🚩 Red Flags
- Previous material weakness in internal control over financial reporting related to IT general controls (access and segregation of duties), though reportedly remediated.
📋 Key Facts
- Effective January 13, 2026, the Audit Committee dismissed BPB and appointed CRI as the new independent registered public accounting firm.
- The change was triggered by CRI acquiring certain assets related to the capital markets practice of BPB.
- BPB's audit report for the fiscal year ended December 31, 2024, contained no adverse or qualified opinions.
- A material weakness in internal control over financial reporting (IT general controls) was identified in the period ending June 30, 2024, but was remediated as of December 31, 2024.
- The company reported no disagreements with BPB regarding accounting principles or auditing procedures.
Sensus Healthcare, Inc. announced the appointment of Larry Biscotti to its Board of Directors as a Class I director on January 5, 2026.
📋 Key Facts
- Larry Biscotti was appointed as a Class I director effective January 5, 2026.
- His term is set to expire at the Company's annual meeting in 2028.
- The Board has determined Mr. Biscotti is an independent director per NASDAQ listing standards.
- Compensation will be pro-rata based on what is provided to other non-employee directors.
Sensus Healthcare, Inc. announced the appointment of Eric Sachetta to the Board of Directors as a Class II director and member of the Audit Committee. This appointment fills a vacancy created by the death of William McCall.
🚩 Red Flags
- Vacancy caused by the death of a director (William McCall).
📋 Key Facts
- Eric Sachetta appointed as Class II director on November 10, 2025.
- Term expires at the Company's annual meeting in 2026.
- Appointment fills a vacancy resulting from the death of William McCall.
- Mr. Sachetta will serve on the Audit Committee.
- The Board has determined Mr. Sachetta is an independent director per NASDAQ listing standards.
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures.
📋 Key Facts
- Reporting date: November 6, 2025
- Period covered: Quarter ended September 30, 2025
- The company included non-GAAP financial measures in the press release (Exhibit 99.1)
- Signed by Javier Rampolla, Chief Financial Officer
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a placeholder to incorporate the press release containing the earnings data.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The company released financial results via Exhibit 99.1
- Financial results include non-GAAP financial measures with reconciliations provided.
Sensus Healthcare, Inc. held its Annual Meeting of Stockholders on May 27, 2025. The meeting resulted in the election of a director, approval of an amended incentive plan, and ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on May 27, 2025.
- Anthony Petrelli elected as Class I director for a three-year term expiring in 2028 (4,325,657 votes 'For').
- Stockholders approved the amendment of the 2017 Incentive Plan to extend its term and increase share issuance.
- Non-binding advisory vote on 2024 executive compensation was approved (5,057,473 votes 'For').
- Ratification of Berkowitz Pollack Brant Advisors + CPAs, LLP as independent auditor for fiscal year ending Dec 31, 2025.
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the first quarter of 2025 via a press release.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: First Quarter of 2025
- The filing includes non-GAAP financial measures and reconciliations in Exhibit 99.1
- Signed by Javier Rampolla, Chief Financial Officer
Sensus Healthcare, Inc. announced the resumption of its common stock repurchase program on February 11, 2025. This program was originally authorized in an August 11, 2023, filing.
📋 Key Facts
- Resumption of common stock repurchase program as of February 11, 2025.
- The authorization for this program was previously reported on August 11, 2023.
- Company is listed on the Nasdaq Stock Market under ticker SRTS.
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a vehicle to release the press containing these earnings figures.
📋 Key Facts
- Reporting date of event: February 5, 2025
- Financial period covered: Quarter and Year ended December 31, 2024
- The filing includes non-GAAP financial measures with reconciliations provided in Exhibit 99.1
- Signed by Javier Rampolla, Chief Financial Officer
Sensus Healthcare, Inc. issued a revised press release regarding its Q2 2024 financial results originally released on November 14, 2024. The company explicitly stated that the revisions are not financial in nature.
🚩 Red Flags
- Revision of previously issued earnings-related communications can sometimes signal internal control weaknesses, though the company explicitly denies any impact on financial figures here.
📋 Key Facts
- The filing is a revision of a previously issued press release dated November 14, 2024.
- The revisions pertain to non-GAAP financial measures and other information within the press release.
- The company clarifies that the changes are 'not financial in nature'.
- The revised press release is filed as Exhibit 99.1.
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the third quarter of 2024. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Third Quarter of 2024
- The company included non-GAAP financial measures in the accompanying press release (Exhibit 99.1)
- Signed by Javier Rampolla, Chief Financial Officer
Sensus Healthcare, Inc. announced the immediate resignation of its independent auditor, Marcum LLP, due to independence concerns arising from a merger between Marcum and CBIZ Inc., a service provider to the company. The Audit Committee has appointed Berkowitz Pollack Brant Advisors + CPAs, LLP as the successor auditor.
🚩 Red Flags
- Sudden auditor resignation (Item 4.01).
- Independence concerns cited as the reason for auditor departure.
- Existing material weakness in internal control over financial reporting related to IT general controls.
- Potential for audit delays or increased scrutiny during the transition to a new firm.
📋 Key Facts
- Marcum LLP resigned effective September 5, 2024.
- Resignation is due to independence concerns related to Marcum's impending merger with CBIZ Inc., which provides HR and health insurance services to Sensus.
- The company reported a material weakness in internal control over financial reporting as of June 30, 2024, specifically regarding IT general controls (access restrictions and segregation of duties).
- Berkowitz Pollack Brant Advisors + CPAs, LLP was appointed as the new independent auditor on September 11, 2024.
- The company stated that the previously reported material weakness did not result in any material misstatements to financial statements for the period ended June 30, 2024.
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the second quarter of 2024. The filing serves as a placeholder for the press release containing the company's operational and financial performance data.
📋 Key Facts
- Reported date: August 8, 2024
- Reporting period: Second Quarter of 2024
- The filing includes non-GAAP financial measures with reconciliations provided in Exhibit 99.1
- Ticker symbol: SRTS (Nasdaq)
Sensus Healthcare, Inc. held its Annual Meeting of Stockholders on May 31, 2024. The meeting resulted in the election of two directors and the approval of several corporate amendments and auditor ratifications.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 31, 2024.
- Megan Cornish and Joseph Sardano elected as Class III directors for three-year terms expiring in 2027.
- Stockholders approved an amendment to the Certificate of Incorporation to permit officer exculpation under Delaware law.
- Non-binding advisory vote on 2023 executive compensation was approved.
- Ratification of Marcum LLP as independent registered public accountant for fiscal year 2024.
Sensus Healthcare, Inc. announced the immediate resignation of Dr. John Heinrich from its Board of Directors on May 30, 2024. The company stated that the resignation was not due to any disagreement with management.
📋 Key Facts
- Dr. John Heinrich resigned from the Board of Directors effective May 30, 2024.
- The resignation is reported as being unrelated to any disagreements with the Company's executive officers or management.
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the first quarter of 2024 via a press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: First Quarter of 2024
- The filing includes non-GAAP financial measures and reconciliations in Exhibit 99.1
- Signed by Javier Rampolla, Chief Financial Officer
Sensus Healthcare, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of earnings via press release.
📋 Key Facts
- Reported date: February 8, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The company included non-GAAP financial measures in the accompanying press release (Exhibit 99.1)
- Information under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act
Sensus Healthcare, Inc. announced that director Samuel O’Rear will not stand for reelection at the upcoming 2024 annual meeting of stockholders.
📋 Key Facts
- Director Samuel O’Rear intends to retire and will not seek reelection at the 2024 Annual Meeting.
- The decision was communicated on January 30, 2024.
- The company explicitly stated that the departure is not due to any disagreement with the Company.
Sensus Healthcare, Inc. announced the appointment of Michael Sardano to its Board of Directors, effective February 1, 2024. Mr. Sardano is currently the Company's President and General Counsel.
🚩 Red Flags
- Related-party transaction/appointment: The new director is the son of the current Chairman and CEO.
📋 Key Facts
- Michael Sardano appointed as a Class II director, effective February 1, 2024.
- Term of directorship expires at the Company’s annual meeting in 2026.
- Mr. Sardano is currently the President, General Counsel, and Corporate Secretary.
- Mr. Sardano is the son of the Company's Chairman and CEO, Joseph C. Sardano.